Clear All
11765 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00093-7663-56 00093-7663 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 9, 2019 In Use
42292-0053-05 42292-0053 Erlotinib hydrochloride Erlotinib Hydrochloride 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 28, 2019 Jan 31, 2021 No Longer Used
62332-0565-30 62332-0565 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Jul 9, 2021 In Use
00597-0138-30 00597-0138 Afatinib Gilotrif 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug 8, 2013 In Use
00310-1350-30 00310-1350 Osimertinib Tagrisso 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov 13, 2015 In Use
63304-0135-11 63304-0135 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov 5, 2019 In Use
57894-0080-60 57894-0080 Lazertinib LAZCLUZE 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug 20, 2024 In Use
46708-0567-30 46708-0567 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Jul 9, 2021 In Use
72485-0217-30 72485-0217 Erlotinib hydrochloride Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov 6, 2019 In Use
31722-0264-30 31722-0264 ERLOTINIB ERLOTINIB 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 24, 2024 In Use
51991-0892-33 51991-0892 Erlotinib Hydrochloride Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov 5, 2019 Jul 31, 2025 No Longer Used
70771-1521-03 70771-1521 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Apr 30, 2020 In Use
57894-0240-30 57894-0240 Lazertinib LAZCLUZE 240.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug 20, 2024 In Use
00310-1350-95 00310-1350 Osimertinib Tagrisso 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Mar 15, 2019 In Use
70771-1521-07 70771-1521 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Apr 30, 2020 In Use
57894-0501-01 57894-0501 Amivantamab Rybrevant 350.0 mg/1 Immunotherapy Monoclonal Antibody EGFR, MET Intravenous May 21, 2021 In Use
70437-0240-26 70437-0240 Neratinib Nerlynx 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Jul 17, 2017 In Use
00173-0752-00 00173-0752 Lapatinib TYKERB 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Mar 16, 2007 Nov 30, 2017 No Longer Used
00078-0671-19 00078-0671 Lapatinib TYKERB 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Aug 3, 2016 In Use
68180-0801-36 68180-0801 lapatinib Lapatinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Sep 29, 2020 In Use
00480-3237-51 00480-3237 Lapatinib Lapatinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Dec 19, 2024 In Use
70437-0240-18 70437-0240 Neratinib Nerlynx 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Jul 17, 2017 In Use
42291-0035-15 42291-0035 Lapatinib Lapatinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Mar 12, 2025 In Use
70437-0240-33 70437-0240 Neratinib Nerlynx 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Jul 17, 2017 In Use
72694-0954-01 72694-0954 Pegaspargase Oncaspar 750.0 [iU]/mL Chemotherapy Miscellaneous Agent Enzyme Intramuscular, Intravenous Jan 2, 2020 In Use

Found 11765 results — Export these results